-
Shionogi Pharma’s Kanegasaki Plant Receives “BSI Kitemark™ for Minimized Risk of AMR” Certification for Antimicrobial Manufacturing
-
IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol Across Range of Patient Populations and Difficult-to-Treat Infections
-
Gareth Morgan Named President of Qpex Biopharma, Inc.
-
Shionogi Highlights Japan’s Role in Advancing Global Health in Dialogue With Bill Gates — Discussing the Fight Against Infectious Diseases and the Future of Sustainable Healthcare Models Under the Theme “Japan’s Role in Advancing Global Health Progress”
-
Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek
-
Shionogi & Co., Ltd. Selected for METI’s FY2024 Supplementary Budget Grant Program for Future-Oriented Co-Creation with the Global South — Feasibility Study on the Use of Digital Solutions to Promote Appropriate Use of Japan-Origin Antimicrobials and Hygiene Products in Kenyan Healthcare Facilities
-
Submission of Letter of Intent and Concept Note to the Kenyan Ministry of Health to Accelerate Access to Cefiderocol
-
Shionogi, Nagasaki University, Saraya and Connect Afya Enter into a Comprehensive Partnership Agreement to Support Antimicrobial Stewardship in Kenya
-
ESCMID Global 2025: Shionogi Presents Real-World Data Demonstrating Better Clinical Outcomes When Fetcroja® / Fetroja® (Cefiderocol) Is Used as Empiric or Documented Therapy as Compared To Salvage Therapy for the Treatment of Gram-Negative Bacterial Infections
-
Exclusive Licensing Agreement with Link Healthcare, a Clinigen Company for Cefiderocol in Australia and New Zealand